Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 09 07 2023
accepted: 11 08 2023
medline: 14 9 2023
pubmed: 13 9 2023
entrez: 13 9 2023
Statut: epublish

Résumé

Comprehensive autoantibody evaluation is essential for the management of autoimmune disorders. However, conventional methods suffer from poor sensitivity, low throughput, or limited availability. Here, using a proteome-wide human cDNA library, we developed a novel multiplex protein assay (autoantibody array assay; A-Cube) covering 65 antigens of 43 autoantibodies that are associated with systemic sclerosis (SSc) and polymyositis/dermatomyositis (PM/DM). The performance of A-Cube was validated against immunoprecipitation and established enzyme-linked immunosorbent assay. Further, through an evaluation of serum samples from 357 SSc and 172 PM/DM patients, A-Cube meticulously illustrated a diverse autoantibody landscape in these diseases. The wide coverage and high sensitivity of A-Cube also allowed the overlap and correlation analysis between multiple autoantibodies. Lastly, reviewing the cases with distinct autoantibody profiles by A-Cube underscored the importance of thorough autoantibody detection. Together, these data highlighted the utility of A-Cube as well as the clinical relevance of autoantibody profiles in SSc and PM/DM.

Identifiants

pubmed: 37701440
doi: 10.3389/fimmu.2023.1255540
pmc: PMC10493387
doi:

Substances chimiques

Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1255540

Informations de copyright

Copyright © 2023 Kuzumi, Norimatsu, Matsuda, Ono, Okumura, Kogo, Goshima, Fukasawa, Fushida, Horii, Yamashita, Yoshizaki-Ogawa, Yamaguchi, Matsushita, Sato and Yoshizaki.

Déclaration de conflit d'intérêts

Authors CO, TO, EK, KY, and NG are employed by the company ProteoBridge Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Curr Opin Biotechnol. 2006 Aug;17(4):373-80
pubmed: 16828277
Nature. 2021 Jul;595(7866):283-288
pubmed: 34010947
Genes Cells. 2021 Mar;26(3):180-189
pubmed: 33527666
Arthritis Rheum. 1992 Jun;35(6):667-71
pubmed: 1350907
Nat Commun. 2021 Oct 12;12(1):5947
pubmed: 34642338
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14652-7
pubmed: 12409616
Scand J Rheumatol. 2016 Jan;45(1):36-40
pubmed: 26312949
Lancet. 2003 Sep 20;362(9388):971-82
pubmed: 14511932
Arthritis Rheum. 2012 Feb;64(2):513-22
pubmed: 21987216
Rheumatology (Oxford). 2020 Aug 1;59(8):2109-2114
pubmed: 32030410
Nat Rev Rheumatol. 2018 Apr 20;14(5):290-302
pubmed: 29674612
Arthritis Rheumatol. 2015 Nov;67(11):3016-26
pubmed: 26238292
N Engl J Med. 1975 Feb 20;292(8):403-7
pubmed: 1089199
Front Immunol. 2019 Mar 12;10:444
pubmed: 30915082
PLoS One. 2013;8(4):e60442
pubmed: 23573256
Medicine (Baltimore). 2016 Jun;95(25):e3931
pubmed: 27336883
Clin Rheumatol. 2020 Nov;39(11):3489-3497
pubmed: 32385758
J Autoimmun. 1996 Jun;9(3):379-83
pubmed: 8816974
JAMA Dermatol. 2023 Apr 1;159(4):374-383
pubmed: 36790794
Autoimmun Rev. 2016 Oct;15(10):983-93
pubmed: 27491568
Autoimmun Rev. 2019 Jul;18(7):658-664
pubmed: 31059843
Ann Rheum Dis. 2008 Sep;67(9):1282-6
pubmed: 18063672
Nat Methods. 2008 Dec;5(12):1011-7
pubmed: 19054851
Front Immunol. 2022 May 04;13:893086
pubmed: 35603173
FEBS Lett. 2002 Mar 6;514(1):102-5
pubmed: 11904190
Br J Rheumatol. 1992 Dec;31(12):811-7
pubmed: 1458287
Nat Rev Rheumatol. 2010 Feb;6(2):112-6
pubmed: 20125179
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
J Am Acad Dermatol. 2002 Apr;46(4):626-36
pubmed: 11907524
Ann Rheum Dis. 2016 Apr;76(4):716-720
pubmed: 28283528
Front Immunol. 2018 Mar 26;9:541
pubmed: 29632529
PLoS One. 2014 Jan 14;9(1):e85062
pubmed: 24454792
N Engl J Med. 2009 May 7;360(19):1989-2003
pubmed: 19420368
Genome Res. 2000 Nov;10(11):1788-95
pubmed: 11076863
Nat Clin Pract Rheumatol. 2008 Sep;4(9):491-8
pubmed: 18756274
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Rheumatology (Oxford). 2020 Jul 1;59(7):1626-1631
pubmed: 31665469
Mod Rheumatol. 2002 Sep;12(3):253-5
pubmed: 24387068

Auteurs

Ai Kuzumi (A)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Yuta Norimatsu (Y)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Kazuki M Matsuda (KM)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Chihiro Ono (C)

ProteoBridge Corporation, Tokyo, Japan.

Taishi Okumura (T)

ProteoBridge Corporation, Tokyo, Japan.

Emi Kogo (E)

ProteoBridge Corporation, Tokyo, Japan.

Naoki Goshima (N)

ProteoBridge Corporation, Tokyo, Japan.
Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.

Takemichi Fukasawa (T)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Department of Clinical Cannabinoid Research, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Natsumi Fushida (N)

Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Motoki Horii (M)

Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Takashi Yamashita (T)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Asako Yoshizaki-Ogawa (A)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Kei Yamaguchi (K)

ProteoBridge Corporation, Tokyo, Japan.
Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.

Takashi Matsushita (T)

Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Shinichi Sato (S)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Ayumi Yoshizaki (A)

Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Department of Clinical Cannabinoid Research, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH